ArticleJTO clinical and research reports2026

First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.

Ewa Kalinka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.